This database contains 350 studies, archived under the term: "therapeutic use"
Click here to filter this large number of results.
Treatment of Alzheimer’s disease with a cholinesterase inhibitor combined with antioxidants
A formula (formula F) was prepared to counteract oxidative stress (OS) in the brain. The formula contained the most common antioxidants and was intended to: (a) protect proteins, lipids, DNA and proteoglycans from oxidation (carnosine, coenzyme Q(10), vitamin E, vitamin C, beta-carotene, selenium, L-cysteine and ginkgo biloba); (b) reduce homocysteine (HCy) blood levels (vitamins B(6), […]
Transcultural influences in dementia care: observations from a psychosocial intervention study
Burns, Alistair,
Mittelman, Mary,
Cole, Catherine,
Morris, Julie,
Winter, Jane,
Page, Sean,
Brodaty, Henry
Background: Various models of intervention for caregivers of patients with dementia have been described. There has been little direct comparison of cultural differences between countries and the effect any differences may exert on the outcome of caregiver interventions.; Aims: The aims of the three-country study (USA, Australia and the UK) were to assess whether caregiver […]
3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
Apostolova, Liana G.,
Thompson, Paul M.,
Green, Amity E.,
Hwang, Kristy S.,
Zoumalan, Charleen,
Jack, Clifford R., Jr.,
Harvey, Danielle J.,
Petersen, Ronald C.,
Thal, Leon J.,
Aisen, Paul S,
Toga, Arthur W.,
Cummings, Jeffrey L.,
Decarli, Charles S.
We applied the hippocampal radial atrophy mapping technique to the baseline and follow-up magnetic resonance image data of 169 amnestic mild cognitive impairment (MCI) participants in the imaging arm of the Alzheimer’s Disease Cooperative Study MCI Donepezil/Vitamin E trial. Sixty percent of the subjects with none to mild hippocampal atrophy rated with the visual medial […]
Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment
Abbatecola, Angela M.,
Lattanzio, Fabrizia,
Molinari, Anna M.,
Cioffi, Michele,
Mansi, Luigi,
Rambaldi, Pierfrancesco,
DiCioccio, Luigi,
Cacciapuoti, Federico,
Canonico, Raffaele,
Paolisso, Giuseppe
Objective: Studies have suggested that insulin resistance plays a role in cognitive impairment in individuals with type 2 diabetes. We aimed to determine whether an improvement in insulin resistance could explain cognitive performance variations over 36 weeks in older individuals with mild cognitive impairment (MCI) and type 2 diabetes.; Research Design and Methods: A total […]
Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study
Wroolie, T. E.,
Kenna, H. A.,
Williams, K. E.,
Powers, B. N.,
Holcomb, M.,
Lazzeroni, L.,
Rasgon, N. L.
Background: To determine the effects of memantine on cognition in a normal population of postmenopausal women with putative risk factors for Alzheimer’s disease (AD) using a built-in control for the genetic risk factor for AD (apoE-epsilon4 status).; Methods: A prospective, open-label, 6-month pilot medication trial with memantine and follow-up after discontinuance conducted at the Center […]
Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer’s disease
Wilkinson, David,
Schindler, Rachel,
Schwam, Elias,
Waldemar, Gunhild,
Jones, Roy W.,
Gauthier, Serge,
Lopez, Oscar L.,
Cummings, Jeffrey,
Xu, Yikang,
Feldman, Howard H.
Background: Therapeutic endpoints based on reduced clinical worsening represent clinically relevant and realistic goals for patients suffering from progressive neurodegenerative disorders such as Alzheimer’s disease (AD).; Methods: Data from 906 patients (388 receiving placebo; 518 receiving donepezil) with mild-to-moderate AD [Mini-Mental State Examination (MMSE) score 10-27] were pooled from 3 randomized, double-blind placebo-controlled studies. Clinical […]
The effect of multisensory stimulation on persons residing in an extended care facility
Background: Non-pharmacological interventions, such as multisensory stimulation environments (MSSE), have demonstrated the ability to reduce inappropriate behavior among individuals with Alzheimer’s disease.; Methods: In this study, we compared the incidences of problematic behavior among individuals with Alzheimer’s disease residing in a long-term care facility who were and were not exposed to an MSSE. Retrospective data […]
Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression
Wang, Lucy Y.,
Shofer, Jane B.,
Rohde, Kirsten,
Hart, Kim L.,
Hoff, David J.,
McFall, Yun H.,
Raskind, Murray A.,
Peskind, Elaine R.
Objectives: Agitation/aggression in Alzheimer disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine (NE) release may contribute to the pathophysiology of agitation/aggression in AD. Prazosin, a nonsedating generic medication used for hypertension and benign prostatic hypertrophy, antagonizes NE effects at brain postsynaptic alpha-1 […]
Improvement of spontaneous speech in early stage Alzheimer’s with rivastigmine
Visch Brink, E. G.,
Van Rhee Temme, W.,
Rietveld, T.,
Krulder, J. W. M.,
Van Harskamp, F.,
Van der Cammen, T. J. M.
Objectives: Placebo-controlled trials have shown that rivastigmine can delay cognitive deterioration in patients with mild to moderate Alzheimer’s disease (AD). Benefits on cognitive functioning, as measured with the ADAS-Cog, occur on a daily dose of 6-12 mg when used for at least 6 months. The effect of rivastigmine on the adequacy of spontaneous speech is […]